Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Daxor Corporation stock logo
DXR
Daxor
$9.79
+0.4%		$10.56
$8.56
▼
$14.76
$56.92M0.3514,291 shs11,255 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Daxor Corporation stock logo
DXR
Daxor
+0.41%-2.97%-12.43%-6.32%-27.70%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Daxor Corporation stock logo
DXR
Daxor
$9.79
+0.4%		$10.56
$8.56
▼
$14.76
$56.92M0.3514,291 shs11,255 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Daxor Corporation stock logo
DXR
Daxor
+0.41%-2.97%-12.43%-6.32%-27.70%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Daxor Corporation stock logo
DXR
Daxor
2.50
Moderate BuyN/AN/A

Current Analyst Ratings Breakdown

Latest ODX and DXR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/21/2026
Daxor Corporation stock logo
DXR
Daxor
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingHold (C)
(Data available from 10/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Daxor Corporation stock logo
DXR
Daxor
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Daxor Corporation stock logo
DXR
Daxor
N/AN/AN/AN/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Daxor Corporation stock logo
DXR
Daxor
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Daxor Corporation stock logo
DXR
Daxor
1.34%

Insider Ownership

CompanyInsider Ownership
Daxor Corporation stock logo
DXR
Daxor
51.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Daxor Corporation stock logo
DXR
Daxor
375.84 million2.83 millionNot Optionable

Recent News About These Companies

Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26
October 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/15/3381581/0/en/daxor-accelerates-commercial-expansion-of-next-gen-blood-volume-diagnostic-platform-at-medaxiom-cv-transforum-fall-26.html
Daxor shares new heart failure data from HFSA 2026 meeting
October 14, 2026  |  streetinsider.comhttps://www.streetinsider.com/Corporate+News/Daxor+shares+new+heart+failure+data+from+HFSA+2026+meeting/27184101.html
Daxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026
October 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/14/3380680/0/en/daxor-announces-strong-commercial-interest-and-new-clinical-data-at-hfsa-2026.html
Daxor to Showcase Blood Volume Analysis Platform at ASN Kidney Week 2026
October 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/13/3379639/0/en/daxor-to-showcase-blood-volume-analysis-platform-at-asn-kidney-week-2026.html
Daxor Corporation (NASDAQ:DXR) Sees Large Growth in Short Interest
October 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109945
Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026
October 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3372839/0/en/daxor-to-showcase-next-gen-blood-volume-analyzer-and-new-clinical-data-at-hfsa-2026.html
Daxor consensus price target decreased by 13.04% to $20.40
September 15, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/daxor-consensus-price-target-decreased-by-13-04-to-20-40/ar-AA2ciBfX
Daxor Corporation to Participate in Lake Street’s Tenth Annual BIG10 Conference in New York City
September 8, 2026  |  quiverquant.comQ
Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3358214/0/en/daxor-corporation-to-participate-in-the-10th-annual-lake-street-best-ideas-growth-conference.html
Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354067/0/en/daxor-corporation-ceo-and-president-michael-feldschuh-delivers-1st-half-corporate-update-in-shareholder-letter.html
Daxor (DXR) Stock Forecast & Price Target
August 11, 2026  |  investing.comhttps://www.investing.com/equities/daxor-corp-consensus-estimates
Daxor Launches Blood Testing Lab in Eastern Kansis
July 31, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/daxor-launches-blood-testing-lab-092745616.html
Daxor Corporation Launches Outpatient Blood Volume Analysis Program at Kansas Healthcare Facility
July 29, 2026  |  quiverquant.comQ
Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas
July 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/30/3335716/0/en/daxor-broadens-outpatient-footprint-with-initiation-of-ezbva-lab-diagnostic-services-in-kansas.html
Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas
July 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/07/3323084/0/en/daxor-corporation-announces-first-time-exhibition-at-the-14th-annual-dysautonomia-international-conference-in-the-woodlands-texas.html
Daxor Stock Dividends | NASDAQ:DXR | Benzinga
June 26, 2026  |  benzinga.comhttps://www.benzinga.com/quote/DXR/dividends
Daxor Shareholders Reelect Board and Ratify Auditor
June 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/daxor-shareholders-reelect-board-and-ratify-auditor?utm_source=marketbeat.com&utm_medium=referral
Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor
June 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/02/3305113/0/en/daxor-corporation-receives-u-s-patent-for-breakthrough-remote-blood-volume-monitor.html
Daxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume Analysis
April 28, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/daxor-leverages-medaxiom-cv-transforum-spring-26-to-accelerate-commercial-adoption-of-blood-volume-analysis-1036071514
Daxor Leverages MedAxiom CV Transforum Spring'26 to Accelerate Commercial Adoption of Blood Volume Analysis
April 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/28/3282545/0/en/daxor-leverages-medaxiom-cv-transforum-spring-26-to-accelerate-commercial-adoption-of-blood-volume-analysis.html

Media Sentiment Over Time

Daxor stock logo

Daxor NASDAQ:DXR

$9.79 +0.04 (+0.41%)
Closing price 10/21/2026 03:59 PM Eastern
Extended Trading
$9.80 +0.01 (+0.10%)
As of 10/21/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas